{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-322950","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.341893+00:00","generated_at":"2026-05-16T12:56:08.979619+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development","bullets":["Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).","Mean ~95% reduction in central subfield intraretinal fluid; no dose-limiting toxicities or TH103-related serious AEs.","Two transient IOI cases at 2.5 mg resolved with manufacturing process change; zero new IOI in 6 subsequent subjects.","31% of patients (4/13) required no additional anti-VEGF treatment during the 6-month follow-up after a single injection.","Plasma Cmax 27–51-fold lower vs. leading anti-VEGF agents; Phase 1b/2 enrollment ongoing, preliminary data expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-322950","json":"https://secwatch.observer/filing/0001193125-25-322950.json","markdown":"https://secwatch.observer/filing/0001193125-25-322950.md","text":"https://secwatch.observer/filing/0001193125-25-322950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/0001193125-25-322950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:56:08.979619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}